




# Does Poland have the potential to become the next cancer research hub?




Wiktor Janicki  
Country President AstraZeneca Poland


FACILITATE DEBATE ACTIVATE INNOVATE

# Poland and its potential in industry CTs

*Global Industry CTs market share  
Year 2019, All Phases*




Source: Industry Clinical trials in Poland report, 2019



Source: World Health Organization, 2023

# And the sites in Poland deliver



Source: Industry Clinical trials in Poland report, 2019

US FDA Bioresearch monitoring inspections 2008-2020 US FDA and severity of findings

US FDA Bioresearch Monitoring Inspections								
	Finding severity 2008-2013			2008-2013 # Inspections	Finding severity 2014-2020			2014-2020 # Inspections
	NAI	OAI	VAI		NAI	OAI	VAI	
<b>North America</b>	<b>50,9%</b>	<b>6,8%</b>	<b>42,3%</b>	<b>2253</b>	<b>67,6%</b>	<b>2,0%</b>	<b>30,4%</b>	<b>3423</b>
United States	50,8%	6,9%	42,3%	2215	67,1%	2,0%	31,0%	3331
Canada	55,3%	2,6%	42,1%	38	88,0%	1,1%	10,9%	92
<b>Western Europe</b>	<b>49,5%</b>	<b>0,9%</b>	<b>49,5%</b>	<b>214</b>	<b>71,2%</b>	<b>0,9%</b>	<b>27,9%</b>	<b>337</b>
Germany	51,8%	0,0%	48,2%	56	79,7%	0,0%	20,3%	59
United Kingdom	33,3%	3,3%	63,3%	30	74,3%	0,0%	25,7%	35
Spain	73,3%	6,7%	20,0%	15	65,9%	0,0%	34,1%	41
Italy	59,1%	0,0%	40,9%	22	64,4%	0,0%	35,6%	45
France	50,0%	0,0%	50,0%	38	73,5%	4,4%	22,1%	68
Belgium	66,7%	0,0%	33,3%	6	68,4%	0,0%	31,6%	19
Netherlands	44,4%	0,0%	55,6%	9	66,7%	0,0%	33,3%	21
Norway	66,7%	0,0%	33,3%	6	100,0%	0,0%	0,0%	1
<b>Eastern Europe</b>	<b>64,0%</b>	<b>0,5%</b>	<b>35,5%</b>	<b>203</b>	<b>79,3%</b>	<b>0,0%</b>	<b>20,7%</b>	<b>280</b>
Poland	69,1%	0,0%	30,9%	55	72,7%	0,0%	27,3%	88
Bulgaria	28,6%	0,0%	71,4%	7	87,5%	0,0%	12,5%	16
Czech Republic	61,1%	0,0%	38,9%	18	84,0%	0,0%	16,0%	25
Hungary	60,0%	0,0%	40,0%	10	67,6%	0,0%	32,4%	34
Romania	66,7%	0,0%	33,3%	12	86,1%	0,0%	13,9%	36
Slovakia	33,3%	0,0%	66,7%	3	100,0%	0,0%	0,0%	3

Source: <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-classification-database>

# How it all started

In 2011 AstraZeneca made a decision to locate its new Global R&D Center in Poland

It started with a team of 60 CT professionals

# Key factors for the establishment of Global R&D Center

## External

## Internal

Lifescience talent

Ability to take risk

Human capital  
potential

Experienced team

Good university  
base


Labour arbitrage

Strong and stable  
GDP growth

Track record of  
delivery



# How it developed – stem cell culture



# Examples of functions created

Data Management

CT supply chain

Global CT Safety Review

Global CT management


CT transparency

Centralized Monitoring

CT systems support


# AstraZeneca current presence in Poland

No. of AZ employees in Poland





# What is the future of cancer CTs in Poland?



- Significant patient unmet need
- Clinical trials recognized by the government as an important part of R&D efforts
- Movement towards earlier phase trials
- Growing investigator base

Source: Industry Clinical trials in Poland report, 2019